 | |
| Company type | Private[1] |
|---|---|
| Industry | Biopharmaceuticals |
| Founder | David H. Kirn[1] |
| Fate | acquired by SillaJen, Inc. |
| Headquarters | 450 Sansome Street, 16th Floor, San Francisco, California , |
Number of locations | 4 (USA, Canada, South Korea) |
| Products | Pexa-Vec (JX-594), JX-929[1] |
| Owner | SillaJen, Inc. |
Number of employees | ~50 |
| Website | www.sillajen.com |
Jennerex Biotherapeutics, Inc. (now owned by SillaJen) was an American private biopharmaceutical company[1][3] that developed the oncolytic viruses JX-594[1][4] and JX-929[1] among others. By creating oncolytic viruses that can (1) kill tumor cells directly through lysis, (2) activate the immune system by delivering genes that encode immunostimulants and by overcoming tumor cell-induced immunological tolerance, and (3) reduce tumor nutrient supply through the destruction of blood vessels, Jennerex aimed to create a novel approach to treating and possibly curing cancer.
- ^ a b c d e f "Jennerex facts sheet: Q3 2012" (PDF). 2012. Archived from the original (PDF) on February 28, 2013. Retrieved September 23, 2012.
- ^ Cite error: The named reference
Jennerex Contact Infowas invoked but never defined (see the help page). - ^ "Jennerex website". 2012. Retrieved September 9, 2012.
- ^ Breitbach C.J.; Burke J.; Jonker D.; Stephenson J.; Haas A.R.; Chow L.Q.M.; Nieva J.; Hwang T.H.; Moon A.; Patt R.; Pelusio A.; Le Boeuf F.; Burns J.; Evgin L.; De Silva N.; Cvancic S.; Robertson T.; Je J.-E.; Lee Y.-S.; Parato K.; Diallo J.-S.; Fenster A.; Daneshmand M.; Bell J.C.; Kirn D.H. (2011). "Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans". Nature. 477 (7362): 99–102. doi:10.1038/nature10358. PMID 21886163. S2CID 4365604.